BRAF and metastatic melanoma: Three BRAF inhibitors (vemurafenib, dabrafenib, and encorafenib) and three MEK inhibitors (trametinib, cobimetinib, and binimetinib) are permitted for metastatic melanoma with BRAF V600E or V600K mutations as a single agent or in combination with other agents and exhibit excellent efficacies.283